HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Summer Sale Get Elite for just $199.50
00
Days
00
Hours
00
Mins
00
Sec
Claim Now
Market News Market Pulse Stocks News ETF News Crypto News

Nuvectis Pharma, Inc.

Contributing Author

Recent Articles by Nuvectis Pharma, Inc.

Jun-29
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock NVCT -35.54% GlobeNewswire
Jun-29
Nuvectis Pharma Announces Proposed Public Offering of Common Stock NVCT NVCT -35.54% GlobeNewswire
Jun-22
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds NVCT +19.61% GlobeNewswire
May-14
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ NVCT GlobeNewswire
May-05
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights NVCT +9.22% GlobeNewswire
Mar-31
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting NVCT GlobeNewswire
Feb-11
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights NVCT GlobeNewswire
Dec-17
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC NVCT GlobeNewswire
Nov-25
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC NVCT GlobeNewswire
Nov-04
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights NVCT -7.55% GlobeNewswire
Nov-04
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights NVCT -7.55% GlobeNewswire
Oct-27
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics NVCT +5.65% GlobeNewswire
Oct-16
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics NVCT GlobeNewswire
Sep-25
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors NVCT GlobeNewswire
Sep-04
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference NVCT GlobeNewswire
Aug-11
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 NVCT NVCT +11.26% GlobeNewswire
Aug-05
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights NVCT -5.35% GlobeNewswire
Jul-31
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study NVCT -7.81% GlobeNewswire
Jul-08
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies NVCT GlobeNewswire
May-16
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference NVCT +6.36% NVCT +10.94% GlobeNewswire
May-06
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights NVCT GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)